Clinical trial by 5-aminolevulinic acid for Alzheimer disease
Phase 2
Active, not recruiting
- Conditions
- Early phase of Alzheimer disease
- Registration Number
- JPRN-jRCTs041180135
- Lead Sponsor
- Matsukawa Noriyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1) Clinical diagnose as Alzheimer disease following NINCDS-ADRDA criteria
a) memory disorder and other connitive dysfunction
b) progressive impairment of cognitive function
2) MMSE 20-24
3) FAST stage 3-4
4) rule out of conscious disorder and/or any psychiatric disease
5) 50-90 years-old
6) written document of informed consent
Exclusion Criteria
1) patients with psychiatric symptom affecting cognitive estimation
2) patients with hearing disorder affecting cognitive estimation
3) patients with physiological disorder affecting cognitive estimation
4) patients under impossible phrmaceutical manegement
5) patients under impossible MRI image of head
6) patients judged as unsuitable by madical doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method